Cargando…
bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574487/ https://www.ncbi.nlm.nih.gov/pubmed/36245284 http://dx.doi.org/10.1002/ctm2.1086 |
_version_ | 1784811113893855232 |
---|---|
author | Xu, Gehan Cui, Liang Li, Jin Wang, Quanren Li, Pansong Xia, Xuefeng Yi, Xin Guan, Quanlin Xu, Jianming |
author_facet | Xu, Gehan Cui, Liang Li, Jin Wang, Quanren Li, Pansong Xia, Xuefeng Yi, Xin Guan, Quanlin Xu, Jianming |
author_sort | Xu, Gehan |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9574487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95744872022-10-17 bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy Xu, Gehan Cui, Liang Li, Jin Wang, Quanren Li, Pansong Xia, Xuefeng Yi, Xin Guan, Quanlin Xu, Jianming Clin Transl Med Letter to the Editor John Wiley and Sons Inc. 2022-10-17 /pmc/articles/PMC9574487/ /pubmed/36245284 http://dx.doi.org/10.1002/ctm2.1086 Text en © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Letter to the Editor Xu, Gehan Cui, Liang Li, Jin Wang, Quanren Li, Pansong Xia, Xuefeng Yi, Xin Guan, Quanlin Xu, Jianming bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy |
title | bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy |
title_full | bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy |
title_fullStr | bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy |
title_full_unstemmed | bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy |
title_short | bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy |
title_sort | bmsaf is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574487/ https://www.ncbi.nlm.nih.gov/pubmed/36245284 http://dx.doi.org/10.1002/ctm2.1086 |
work_keys_str_mv | AT xugehan bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy AT cuiliang bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy AT lijin bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy AT wangquanren bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy AT lipansong bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy AT xiaxuefeng bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy AT yixin bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy AT guanquanlin bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy AT xujianming bmsafisaprognosticpredictorforadvancedhepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorcamrelizumabandantiangiogenicagentapatinibcombinationtherapy |